Related Experiment Video

Updated: May 17, 2026

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Targeting the Ras-ERK pathway in pancreatic adenocarcinoma

Cindy Neuzillet1, Pascal Hammel, Annemilaï Tijeras-Raballand

  • 1INSERM U728 and Department of Medical Oncology, Beaujon University Hospital (AP-HP Paris 7 Diderot), Clichy, France.

Cancer Metastasis Reviews
|October 23, 2012
PubMed

Insights

Pancreatic cancer (PAC) has poor prognosis. Targeting the Ras-ERK pathway, driven by K-RAS mutations, offers a new therapeutic strategy by blocking cancer cell survival and metastasis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Pancreatic ductal adenocarcinoma (PAC) is a lethal digestive tract cancer with limited treatment options.
  • PAC development involves inactivation of tumor suppressor genes and activation of oncogenes, notably K-RAS mutations.
  • K-RAS mutations initiate early in PAC, activating the Ras-ERK pathway, which promotes cancer cell survival, invasion, and metastasis.

Purpose of the Study:

  • To review the role of the Ras-ERK pathway in pancreatic carcinogenesis.
  • To explore the Ras-ERK pathway as a potential therapeutic target for PAC treatment.

Main Methods:

  • Literature review of studies on pancreatic cancer, K-RAS mutations, and the Ras-ERK pathway.
  • Analysis of preclinical PAC models demonstrating the effects of Ras-ERK pathway inhibition.
  • Examination of clinical trial data for inhibitors targeting downstream kinases in the Ras-ERK pathway.

Main Results:

  • K-RAS mutations are prevalent early events in PAC, driving the Ras-ERK pathway.
  • Inhibition of Ras-ERK pathway components in PAC models effectively blocks cancer cell proliferation and metastasis.
  • Downstream kinase inhibitors (Raf, MEK) show promise and are under clinical evaluation.

Conclusions:

  • The Ras-ERK pathway is a critical driver of pancreatic carcinogenesis.
  • Targeting downstream kinases in the Ras-ERK pathway represents a promising therapeutic strategy for PAC.
  • Further clinical investigation of these targeted therapies is warranted for improved PAC treatment outcomes.

More Related Videos

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...